Sangamo BioSciences Acquires Ceregene
Richmond-based Sangamo BioSciences announced Monday that it is acquiring Ceregene, a biotechnology firm developing adeno-associated virus (AAV) gene therapies. Sangamo said it will issue 100,000 shars of its common stock, plus provide unspecified earnout in the deal. The stock portion of the deal is worth approximately $1.0M, based on Sangamo's recent trading price. Ceregene had been backed by Alta Partners, California Technology Ventures, Cell Genesys, Hamilton BioVentures, Investor Growth Capital Ltd., and MPM Capital, and had raised over $71M in venture funding.
posted on Tuesday, August 27, 2013
Related stories:
> Sangamo Therapeutics Acquires TxCell
> Entelos Acquires Iconix Biosciences
> Cell Biosciences Acquires Convergent Bioscience, Raises Funding
> 3-V Biosciences Finds $20M In Funding
> Pacific Biosciences Raises $50M
silicontap.com Home